Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345013 | 1.00 | KDM4E (0.80) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL29853687 | 0.93 | KDM4E (0.71) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL26768656 | 0.91 | KDM4E (0.69) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5311021 | 0.86 | KDM4E (0.82) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL26785965 | 0.86 | KDM4E (0.61) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL29853731 | 0.86 | KDM4E (0.61) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL382822 | 0.86 | KDM4E (0.66) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL14063326 | 0.85 | KDM4E (0.79) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL20430500 | 0.85 | CYP1A2 (0.85) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2949877 | 0.84 | KDM4E (0.64) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712958-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Vandria SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-08 | — | — | US | disclosed |
| CN-119947717-A | Therapeutic use of urolithin derivatives | 范徳利亚股份公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2024236367-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-11-21 | — | — | WO | disclosed |
| US-20240158363-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| CN-117015530-A | Urolithin derivatives and methods of use thereof | 范徳利亚股份公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3589390-B1 | SELECTIVELY PERMEABLE GRAPHENE OXIDE MEMBRANE | NITTO DENKO CORP (JP) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158363-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885 |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.